Using management algorithms or pathways potentially improves clinical outcomes. We undertook systematic reviews to examine various aspects in the generic approach (use of cough algorithms and tests) to the management of chronic cough in children (aged # 14 years) based on key questions (KQs) using the Population, Intervention, Comparison, Outcome format.
Summary of Recommendations/Suggestions 1. For children aged £ 14 years, we suggest defining chronic cough as the presence of daily cough of at least 4 weeks in duration (Ungraded, Consensus Based Statement).
2. For children aged £ 14 years with chronic cough, we suggest that an assessment of the effect of cough on the child and the family be undertaken as part of the clinical consultation (Ungraded, Consensus Based Statement).
3. For children aged £ 14 years with chronic cough, we recommend using pediatric-specific cough management protocols or algorithms (Grade 1B).
4. For children aged £ 14 years with chronic cough, we recommend taking a systematic approach (such as using a validated guideline) to determine the cause of the cough (Grade 1A).
5. For children aged £ 14 years with chronic cough, we recommend basing the management or testing algorithm on cough characteristics and the associated clinical history, such as using specific cough pointers like presence of productive/wet cough (Grade 1A).
6. For children aged £ 14 years with chronic cough, we recommend basing the management on the etiology of the cough. An empirical approach aimed at treating upper airway cough syndrome due to a rhinosinus condition, gastroesophageal reflux disease, and/or asthma should not be used unless other features consistent with these conditions are present (Grade 1A).
7. For children aged £ 14 years with chronic cough, we suggest that if an empirical trial is used based on features consistent with a hypothesized diagnosis, the trial should be of a defined limited duration in order to confirm or refute the hypothesized diagnosis (Ungraded, Consensus Based Statement).
8. For children aged £ 14 years with chronic cough, we recommend that a chest radiograph and, when age appropriate, spirometry (pre-and post-b 2 agonist) be undertaken (Grade 1B).
9. For children aged £ 14 years with chronic cough, we suggest undertaking tests evaluating recent Bordetella pertussis infection when pertussis is clinically suspected (Ungraded, Consensus Based Statement).
10. For children aged £ 14 years with chronic cough, we recommend not routinely performing additional tests (eg, skin prick test, Mantoux, bronchoscopy, chest CT); these should be individualized and undertaken in accordance with the clinical setting and the child's clinical symptoms and signs (Grade 1B).
11. For children aged > 6 years and £ 14 years with chronic cough and asthma clinically suspected, we suggest that a test for airway hyperresponsiveness (AHR) be considered (Grade 2C).
Chronic cough among children is associated with impaired quality of life, 1 multiple physician visits, 2 and adverse effects from inappropriate use of medications. 3 Also, it may signify a serious underlying disease such as bronchiectasis or an inhaled foreign body. 1 Further, early diagnosis is important, as delayed diagnosis (eg, foreign body) may cause chronic respiratory morbidity, 4 whereas early diagnosis of chronic disease leads to appropriate management and subsequent resolution of cough and improved quality of life (QoL).
1
Use of cough algorithms or pathways can potentially lead to earlier diagnosis and reduce morbidity, unnecessary costs, and medication use associated with chronic cough.
In the management of chronic cough (ie, cough of more than 4 weeks' duration), investigations are undertaken to confirm or rule out specific causes. When undertaking investigations in children, the pediatric-specific issues and risk-benefit ratio needs to be taken into consideration. For example, although respiratory function tests are standard assessments in adults, most young children are unable to generate reliable data from pulmonary function tests (such as spirometry and AHR challenges) until the age of 6 years in most clinical laboratories. Chest CT scans are associated with higher adverse events in young children (future cancer) 5 and may require a general anesthetic in children aged < 3 years. In this paper, our overall aim was to present the recommendations and the summary of evidence behind these recommendations relating to the assessment and use of management pathways or algorithms in children with chronic cough. Systematic reviews addressing PICOformatted KQs relating to various aspects of cough algorithms were undertaken and previously published in part and are best read together with this document. 7 
Methods
For the CHEST cough guidelines, it was a priori determined that the age cutoff for pediatric and adult components was 14 years. We used a standard method 8 as previously described by Vertigan, et al : "The methodology used by the CHEST Guideline Oversight Committee to select the Expert Cough Panel Chair and the international panel of experts, perform the synthesis of the evidence and develop the recommendations and suggestions has been published. 8, 10 Key questions and parameters of eligibility were developed for this topic. Existing guidelines, systematic reviews, and primary studies were assessed for relevance and quality, and were used to support the evidence-based graded recommendations or suggestions. A highly structured consensus-based Delphi approach was employed to provide expert advice on all guidance statements. The total number of eligible voters for each guideline statement varied based on the number of managed individuals recused from voting on any particular statements because of their potential conflicts of interest. Transparency of process was documented. Further details of the methods have been published elsewhere. 8, 10 Consistent with recent recommendations from the Institute of Medicine, the Panel conducted a comprehensive, systematic review of the literature to provide the evidence base for this guideline."
Guideline Framework
As previously described, 9 "the ACCP has adopted the GRADE framework (The Grading of Recommendations Assessment, Development and Evaluation). This framework separates the process of rating the quality of evidence from that of determining the strength of recommendation. The quality of evidence is based on the five domains of risk of bias, inconsistency, indirectness, reporting bias and imprecision. The quality of evidence (ie, the confidence in estimates) is rated as high (A), moderate (B), low or very low (C). The strength of recommendation is determined based on the quality of evidence, balance of benefits and harms, patients' values and preferences, and availability of resources. Recommendations can be strong or weak."
State of the Available Evidence
Searches for the systematic reviews were undertaken externally by librarians (Nancy Harger, MLS and Judy Nordberg, MLS) from the University of Massachusetts Medical School, Worcester, MA. These searches were undertaken between February 28, 2015 and August 14, 2015 using an a priori established protocol for each KQ. 7 The evidence for three KQs was summarized in a previous publication 7 (and key tables and figures in e-Appendix 1, e- Tables  1-3 , and e-Figs 1-3) and reproduced in e-Appendix 1, e- Tables 4  and 5 The systematic reviews 7 (and e-Appendix 1, e- Tables 4 and 5 , e-Figs 4 and 5) identified high-quality evidence to support some recommendations but not all. When there was insufficient evidence for diagnosis and management recommendations, the panel heavily placed great emphasis on patient values, preferences, ease and cost of tests, and availability of potential therapies. The panel also made several suggestions for future research.
Results
The first eight recommendations and/or suggestions were derived from systematic reviews that addressed KQs 1 to 3 summarized in e- Tables 1-3 and e- Figures 1-3 . 7 The subsequent four recommendations/suggestions were derived from systematic reviews that addressed KQs 4 and 5 (all summarized in e- Tables 4 and 5 and e-Figs 4 and 5).
Summary of Evidence and Interpretation
The definition of the duration of chronic cough is controversial, because in a minority of children, cough after viral infections lasts > 4 weeks. In our systematic review, 7 (e -Tables 1 and 2) , we found no studies that addressed the question of whether the cough management or testing algorithm should differ depending on the journal.publications.chestnet.org duration of chronic cough (KQ 2). Also to date, there are no published studies that have clinically assessed the possible reasons and/or outcomes of the group of children with acute cough that persists for > 4 weeks.
In reviewing published national guidelines, we found that all but one 11 guideline defined chronic cough in children as a duration lasting > 4 weeks (e- Table 2 ). All the guidelines (such as those of ACCP, 6 and the Thoracic Society of Australia and New Zealand
12
) that use the shorter time frame do not advocate the use of medications or investigations for all children at that time point, recognizing that the cough subsides without any specific treatment in a number of children (ie, assumed "resolved spontaneously"). 1, 13 The shorter time frame is recommended for reasons outlined in previous publications. 1, 12 One such reason is to ensure that all children with chronic cough are carefully assessed and not quickly dismissed as having a postviral cough. This is particularly important in children, as chronic cough may be due to a serious underlying condition, and earlier diagnosis and treatment results in less damage (eg, retained foreign body 4 and bronchiectasis 14 ). Indeed, a serious potentially progressive underlying respiratory illness (bronchiectasis, aspiration lung disease, or cystic fibrosis) was documented in 18% of children in a multicenter study that used a cough algorithm. 1 Thus, for safety reasons, we advocated that chronic cough should be defined as that lasting > 4 weeks.
1. For children aged £ 14 years, we suggest defining chronic cough as the presence of daily cough of at least 4 weeks in duration (Ungraded, Consensus Based Statement).
Summary of Evidence and Interpretation
Our systematic review 7 found no eligible studies that examined whether the cough testing algorithm should differ depending on the severity of the cough (e- Table 2 ). Almost all existing nationally based cough guidelines suggest that cough severity should be assessed, along with burden and expectations. However, these recommendations are generic, with little detail regarding how to assess cough severity.
Although cough is often dismissed by health professionals as a minimal ailment, cough causes substantial burden. In a prospective multicenter cohort study 1 2. For children aged £ 14 years with chronic cough, we suggest that an assessment of the effect of cough on the child and the family be undertaken as part of the clinical consultation (Ungraded, Consensus Based Statement).
Our systematic review 7 found high-quality evidence that in children aged # 14 years with chronic cough (> 4 weeks' duration), the use of children-specific cough management protocols (or algorithms) improves clinical outcomes (e- Table 1 ). When data were available, findings from randomized controlled trials (RCTs) were consistent with those derived from cohort studies. 7 All studies within the past decade used systematic evaluation of the child.
The highest evidence for the type of chronic cough pathway was that derived from the American College of Chest Physicians, 6 as the evidence was derived from an RCT 19 and several cohort studies. [20] [21] [22] The evidence for other pathways was restricted to single studies (e- Table 1 ). The variations in algorithms raise the question of whether algorithms that are specific to the clinical setting should be used, such as in developing countries, where the most common causes of cough are likely different (eg, tuberculosis, parasitic disease). However, irrespective of the relative prevalence of different conditions, the correct diagnosis would be obtained if a cough pathway such as the CHEST guideline is used.
Our systematic reviews 7 also found high-quality evidence that in children (aged #14 years) with chronic cough, the cough management or testing algorithm should differ depending on the associated characteristics of the cough and clinical history (e-Tables 3a, 3b). We 7 found that all included studies demonstrated that cough management should differ depending on clinical history, including cough characteristics. None of the studies used an empirical approach. At a divergent point, all studies used the concept of wet or productive cough, but the point of when this divergence occurred differed between the algorithms. 7 A study that specifically examined the use of cough pointers 22 found that the presence of any specific (Table 1) 23 is dependent on accurate identification (ie, expertise of physicians and the caregiver's history).
Our systematic review 7 also found that the majority of children in all the studies received treatment specific for the underlying cause rather than an empirical approach based on treatment of gastroesophageal reflux disease, upper airway cough syndrome due to a rhinosinus condition, or asthma (e- Table 3 ). However, in some situations, an empirical trial is required, such as using inhaled corticosteroids when the cough is dry and objective testing cannot be undertaken in a young child. Ascribing causes for the cough has an inherent high risk of bias related to the placebo and "period effects" (the natural resolution of cough over time 24 ) evident in cough-related intervention studies. 25 These risks of bias can be reduced by limiting the time frame in which "response to treatment" is considered, 25 when an RCT is not undertaken.
6. For children aged £ 14 years with chronic cough, we recommend basing the management on the etiology of the cough. An empirical approach aimed at treating upper airways cough syndrome due to a rhinosinus condition, gastroesophageal reflux disease, and/or asthma should not be used unless other features consistent with these conditions are present (Grade 1A).
Of the studies included in our systematic reviews, 7 less than one-half of the studies a priori defined how cough was measured and what constituted cough resolution and/or considered the period effect (e- Tables 1 and 3) . Many also lacked standardization of defining cough outcomes. Thus, further high-quality studies using validated tools, 26 particularly in primary care settings, are needed. This includes use of methods that take into account the period effect and use of a priori definitions for cause and response using validated pediatric-specific cough outcome measures such as the PC-QOL. 16, 27 Several but not all guidelines recommend that chest radiographs and spirometry be undertaken in all children presenting with chronic cough (Table 2) . [28] [29] [30] [31] [32] In KQ4, our systematic review examined whether any routine investigations should be undertaken in all children with chronic cough, and in KQ5, we evaluated specific cohorts that related to more complex lung function tests.
For KQ4 (e -Fig 4, e- Table 4 ), we identified one RCT, 19 undertaken in pediatric pulmonology clinics, in which management was based on identification of cough pointers ( Table 1 ) that included abnormalities detected on the chest radiograph and spirometry. The rest of the included studies were lower-quality studies; two were retrospective studies 33, 34 and nine were prospective studies. [20] [21] [22] [35] [36] [37] [38] [39] [40] One of the prospective studies 41 included children in the RCT 19 that calculated the LRs of the utility of spirometry and chest radiograph. For both tests, the positive LRs were infinite, but negative LRs were not highly negative, indicating that both tests are good for ruling in disease when abnormalities are present but poor at ruling out disease. For example, abnormal spirometry values at baseline with bronchodilator reversibility provide objective evidence consistent with asthma. However, asthma cannot be ruled out when spirometry values are normal. Results from these studies indicate that the risk-benefit ratio of both spirometry and chest radiograph clearly favors the benefit arm.
Although our search identified several studies evaluating the prevalence of recent B pertussis infection in children with cough, these studies 42, 43 did not fulfill our systematic review's inclusion criteria of cough duration. 36, 37 Although the studies reported a mean cough duration of > 4 weeks (range not given), the inclusion criteria for both studies was > 2 weeks. Nevertheless, these studies, conducted in primary care, suggested that appropriate tests to evaluate for recent pertussis infection should be undertaken when clinically appropriate. The most appropriate test (culture, polymerase chain reaction, or serologic analysis) is dependent on the child's age and duration of symptoms. 44 The 2006 ACCP guideline 6 advocated that testing for recent B pertussis infection be undertaken when clinically suspected (eg, contact, posttussive vomiting, whoop), as described in several studies. Other than chest radiograph and spirometry, few studies have systematically undertaken tests in the cohorts of children. Skin prick testing to assess atopy, undertaken in several studies, 33, 35, 38 was generally not useful in aiding the diagnosis of chronic cough. This is not surprising, as although atopy increases the probability of having asthma, it presence or absence is a poor sole distinguishing feature for pediatric asthma. 45 In a study involving 202 children, atopy (defined by skin prick testing) did not influence cough receptor sensitivity to capsaicin. 46 One study 36 undertaken in a setting with a high prevalence (relative to affluent countries) of tuberculosis found that sequential testing (including a Mantoux test) identified tuberculosis in 22% of the 94 children. This study 36 and other studies [19] [20] [21] [22] 37, 39, 40 that undertook tests in accordance with the clinical findings suggest that other than chest radiograph and spirometry, other tests should be targeted. Another such example is provided by data from an Iranian study 47 (excluded because inclusion criteria was > 2 weeks of cough), that described a high frequency of Toxocara IgG, peripheral blood eosinophilia, and hypereosinophilia (14%, 55%, and 80%, respectively) in children with chronic cough.
19-22,40
Summary of Evidence and Interpretation
Four relevant studies 33, 35, 38, 48 were included in the systematic review for KQ5 (e- Fig 5, e- Table 5 ). There were no RCTs. One was a retrospective study and three were prospective single-center studies that undertook different types of bronchoprovocation investigations. The definition of presence of AHR varied among the studies. One study 38 included children with wheeze, two 33, 35 excluded a history of wheeze, and the remaining study 48 did not specify or mention wheeze in the inclusion or exclusion criteria. However, one 35 of the studies that excluded children with wheeze included children with exertional dyspnea. None of the studies were of high quality, but all studies showed that AHR suggestive of asthma was demonstrated in a subgroup of children with chronic cough. Oral theophylline was used in two studies, 33, 35 and both reported rapid cessation of cough. Some children in the latter study, 33 a retrospective review of charts, were also treated with an oral or inhaled shortacting b 2 agonist. Thus, there are insufficient data to recommend that testing for AHR should be undertaken in all children with chronic cough. When asthma is suspected and/or other symptoms are present (eg, history of wheeze, exertional dyspnea, history of atopy), we suggest that testing for AHR should be considered (if possible) when the spirometry values are normal and other concurrent evidence of asthma is not evident. As it is beyond our scope to discuss the role of AHR and skin prick testing in the evaluation of asthma or rhinitis, readers are referred to asthma and/or rhinitis guidelines. As testing for AHR in clinical laboratories (as opposed to research laboratories) is only validly performed in children aged > 6 years, the recommendation is restricted to this age group.
Areas for Further Research
To advance and improve the management of chronic cough in children, suggested areas of research include the following:
1. Undertake multicenter cohort studies in various clinical settings (community and hospital) that assess the outcomes of children with acute cough that then progresses to chronic cough. 2. Undertake RCTs on the efficacy of cough in various clinical settings, particularly in primary care. When doing so, we suggest that validated cough outcomes, a priori definitions, and "period effect" considerations be used. 3. Delineate the risk-benefit ratio of using different definitions of cough durations (eg, 4 weeks, 8 weeks,appropriate training given to primary care practitioners. 5. Evaluate whether cough management or testing algorithms should depend on the duration and/or severity in children with chronic cough. 6. Determine the most appropriate age cutoff used for pediatric vs adult chronic cough guidelines (eg, 12, 14, 18 years).
Conclusions
In the past decade, the availability of single-center and multicenter studies from several countries has improved the evidence base of the 2006 CHEST Cough Guidelines 6 approach. The new recommendations formulated from systematic reviews addressing five KQs were endorsed by the CHEST Expert Cough Panel. Although there is highquality evidence for some of the new recommendations, many questions remain, particularly in primary care for which there is scarcity of data.
